Literature DB >> 35462645

Revisiting Combination Chemotherapy as a Single Modality Palliative Therapy for Advanced Anaplastic Thyroid Carcinoma-a Single Institution Experience.

Surabhi Garg1, Sasi Mouli1, Kul Ranjan Singh1, Pooja Ramakant1, Anand K Mishra1, Chanchal Rana1.   

Abstract

Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy with dismal outcome especially in metastatic setting. Consensus for ideal treatment of advanced and metastatic ATC remains elusive. This study aimed to analyze the impact of palliative chemotherapy versus supportive care on overall survival in patients with metastatic anaplastic thyroid carcinoma. Patients diagnosed with ATC between the period January 2018 and December 2019 were prospectively followed. The patients opting for palliative chemotherapy received 3 weekly Paclitaxel (175 mg/m2) and Carboplatin (AUC-5). Out of the 31 patients diagnosed with ATC, clinicopathological profile of 29 patients was analyzed (2 patients who underwent upfront surgical resection with curative intent were excluded), out of which 20 patients were included in the survival analysis. The median age of presentation was 55.8 years with male:female ratio 1.9:1. Seventeen out of the total 29 patients presented with anaplastic transformation in long-standing goiter. Nineteen out of 20 (95%) patients presented with distant metastasis with lungs being the most common site. Nodal metastasis was present in all patients. Invasion of the strap muscles (90%) and trachea (80%) was the most common peri-thyroidal tissue invasion followed by invasion of the esophagus (40%), internal jugular vein (30%), and carotid artery (5%). Twelve out of the 20 patients opted for palliative chemotherapy. Overall, median survival from the time of diagnosis was 2.6 months, with median survival in patients receiving chemotherapy 3.1 months and those opting for supportive care 1.6 months (p=0.004). Out of all the factors analyzed, male sex (HR 6.521, 95% CI 1.143-37.206, p value 0.03) and vascular invasion (HR 0.066, 95% CI 0.009-0.499, p value 0.008) were poor prognostic indicators. Palliative chemotherapy showed increased survival benefit in patients with metastatic ATC. Male sex and vascular invasion were found to be significant factors associated with poor outcomes on Cox regression analysis. © Indian Association of Surgical Oncology 2021.

Entities:  

Keywords:  Anaplastic; Thyroid cancer; Undifferentiated carcinoma

Year:  2021        PMID: 35462645      PMCID: PMC8986910          DOI: 10.1007/s13193-021-01401-w

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  19 in total

1.  A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients.

Authors:  B Busnardo; O Daniele; M R Pelizzo; R Mazzarotto; D Nacamulli; D Devido; C Mian; M E Girelli
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

2.  Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group.

Authors:  K B Ain; M J Egorin; P A DeSimone
Journal:  Thyroid       Date:  2000-07       Impact factor: 6.568

3.  Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma.

Authors:  Takuya Higashiyama; Yasuhiro Ito; Mitsuyoshi Hirokawa; Mitsuhiro Fukushima; Takashi Uruno; Akihiro Miya; Fumio Matsuzuka; Akira Miyauchi
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

Review 4.  Anaplastic thyroid carcinoma: current diagnosis and treatment.

Authors:  D Giuffrida; H Gharib
Journal:  Ann Oncol       Date:  2000-09       Impact factor: 32.976

Review 5.  Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.

Authors:  R C Smallridge; J A Copland
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-04-24       Impact factor: 4.126

Review 6.  Chemoradiation in anaplastic thyroid carcinomas.

Authors:  X S Sun; S R Sun; N Guevara; N Fakhry; P Y Marcy; S Lassalle; I Peyrottes; R J Bensadoun; A Lacout; J Santini; L Cals; J F Bosset; A S Garden; J Thariat
Journal:  Crit Rev Oncol Hematol       Date:  2012-12-04       Impact factor: 6.312

7.  Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002.

Authors:  Jergin Chen; Jonathan D Tward; Dennis C Shrieve; Ying J Hitchcock
Journal:  Am J Clin Oncol       Date:  2008-10       Impact factor: 2.339

8.  Predictors of Regional Lymph Node Recurrence after Initial Thyroidectomy in Patients with Thyroid Cancer.

Authors:  Amirsina Sharifi; Abolfazl Shojaeifard; Ahmadreza Soroush; Mehdi Jafari; Ali Ghorbani Abdehgah; Hossein Mahmoudzade
Journal:  J Thyroid Res       Date:  2016-06-14

9.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

10.  Evidence from an updated meta-analysis of the prognostic impacts of postoperative radiotherapy and chemotherapy in patients with anaplastic thyroid carcinoma.

Authors:  Quansong Xia; Wei Wang; Juan Xu; Xue Chen; Zhaoming Zhong; Chuanzheng Sun
Journal:  Onco Targets Ther       Date:  2018-04-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.